The nation of Zimbabwe has rejected a significant US health deal valued at $367m (£272m) over five years because of Washington's demand for confidential information.
The decision became public after a government memo from December was disclosed, indicating that Head of State Emmerson Mnangagwa believed the deal was "unbalanced".
A government representative later explained that the US was demanding access to health data for research and commercial purposes but was not willing to share the benefits from future treatments.
"We are forced to start the challenging and unfortunate process of winding down our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the US had donated over $1.9bn as health assistance to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has urged further dialogue to secure a deal agreeable to all parties so the nation's critical HIV programme can be sustained.
Broader Background
This rejection comes after a comparable case in neighbouring Kenya, where a high court suspended a similar health funding agreement following legal challenges were filed about the safety of Kenyans' health data.
Since resuming office last year, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
USAID had managed aid for the American government, but Trump claimed its spending was "inefficient" and his administration was pursuing direct bilateral agreements to boost transparency and accountability.
According to reports, 16 nations in Africa have so far agreed to similar health pacts, representing over $18.3bn in committed funds.
Specifics of the Rejected Deal
The funds for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this cooperation might have yielded immense benefits for Zimbabwean communities, especially the 1.2 million currently receiving HIV treatment through American-funded programmes," the Ambassador added.
However, official spokesman Nick Mangwana said the proposed deal was "unfair".
"Our nation was requested to provide its genetic material and health information for a long time, without any equivalent assurance of benefiting from any scientific breakthroughs – such as new medicines or tests – that could be developed from that provided information," he stated.
"In essence, our country would provide the basic resources for medical research without any assurance that the resulting innovations would be available to our citizens should a new health crisis arise."
Sovereignty and Global Health
He also pointed out that the American exit from the global health body and its push of bilateral deals were undermining structures already set up via the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme designed to deal with potential pandemics.
"This mechanism is intended to ensure that when a nation contributes its samples, the benefits – including medicines and cures – are shared equitably, not commercialised exclusively by those with the funds to create them."
The government's concerns over the US deal "must not be interpreted as anti-American sentiment," he added.
"We welcome ongoing discussions with our American counterparts on how future collaboration might be structured in a way that respects the independence and interests of both nations."
Health Experts Reaction
Medical experts stated it understood the official position, but suggested that talks should continue since much of the country's Aids initiatives were funded by international support.
"In cases where specific concerns exist, such as those relating to information security or agreement terms, these can often be addressed through detailed discussion and mutually agreed protections," it said.
The halted deal highlights the ongoing tensions between accepting vital foreign assistance and protecting national sovereignty in an ever more interconnected world.